Taking Semaglutide Could Cut Dementia Risk Nearly In Half, Case Western Study Shows

CLEVELAND — For millions of Americans taking Ozempic or Wegovy, there might be more good news coming. Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half, according to a large new study.

Researchers tracked health records from over 1.7 million people with Type 2 diabetes and found those taking semaglutide were much less likely to develop Alzheimer’s disease and related dementias. When compared to insulin users, semaglutide reduced dementia risk by 46%. Even against metformin, often the go-to diabetes drug, semaglutide still showed a 33% reduction.

The Need For Better Dementia Treatments

Dementia currently affects more than 6 million Americans and costs our healthcare system roughly $600 billion each year. With no cures available for most types of dementia, preventing it becomes critical. About 45% of dementia cases link back to things we can actually change: diabetes, obesity, high blood pressure, and heart disease. Semaglutide already helps with all of these conditions.

The researchers wrote that their work “provides evidence supporting protective effects of semaglutide on dementias in patients with Type 2 diabetes,” though they emphasized that more research is needed to prove the drug actually causes this protection.

Putting Semaglutide To The Test

Scientists used a method called “target trial emulation” to pit semaglutide against seven other diabetes medications. They analyzed electronic health records from December 2017 through December 2021, following patients for up to three years after starting treatment.

The study, published in the Journal of Alzheimer’s Disease, focused on people with Type 2 diabetes who had no previous history of Alzheimer’s or dementia. Researchers matched participants using statistical techniques to account for differences in age, health conditions, and other factors that might skew results.

All study participants had what researchers called “active and recent” diabetes, meaning they’d had medical visits for their diabetes within the past year and were actively taking medications during the study period.

The protective effects varied depending on which drug researchers compared semaglutide against. The biggest difference showed up against insulin, with users having roughly half the dementia risk. Other comparisons revealed smaller but still meaningful reductions: 33% lower risk versus metformin, 20% lower versus similar drugs in semaglutide’s class, and reductions ranging from 22% to 36% compared to other diabetes treatments.

Not All Dementia Types Benefited Equally

The protection wasn’t uniform across different types of dementia. Semaglutide showed the strongest connection with reduced vascular dementia risk but didn’t seem to affect frontotemporal dementia or Lewy body dementia much. The researchers noted these latter conditions were relatively rare in their study, which may have limited their ability to spot effects.

Adults under 65 saw more dramatic risk reductions (between 32% and 56%) compared to seniors, who experienced reductions of 20% to 40%. Women appeared to benefit slightly more than men, though the differences were modest. Patients with obesity also seemed to get greater protection than those without obesity, hinting that the drug’s weight-loss effects might contribute to its brain-protecting potential.

The Science Behind the Protection

Semaglutide belongs to a drug class called GLP-1 receptor agonists, which copy hormones that help regulate blood sugar. But the medication’s effects reach far beyond glucose control. It reduces inflammation, improves heart health, lowers blood pressure and even affects brain function.

The researchers noted that “semaglutide might represent a multiple-domain intervention with a single component,” explaining that traditional prevention strategies targeting multiple dementia risk factors have shown only modest and inconsistent results.

Animal studies have provided additional clues about how semaglutide might protect the brain. Research in mice with Alzheimer’s-like conditions showed the drug had brain-protective and anti-inflammatory effects. Currently, two large clinical trials are underway specifically testing semaglutide’s effects on early-stage Alzheimer’s disease.

Important Caveats to Consider

Despite the promising results, this study has several important limitations. Most significantly, this was an observational study, not a randomized controlled trial, meaning researchers can’t definitively prove semaglutide caused the reduced dementia risk.

Electronic health records, while valuable for large-scale studies, can have issues like misdiagnosis, underdiagnosis, or missed diagnoses. The study also couldn’t account for factors like how well patients actually took their medications, lifestyle changes, or genetic predisposition to dementia.

The follow-up period was relatively short (just three years) and semaglutide only received approval for diabetes treatment in December 2017, limiting how long researchers could track patients. Additionally, the study looked only at people with Type 2 diabetes, so it’s unclear whether similar benefits would apply to people without diabetes who take semaglutide for weight loss.

Healthcare experts stress these results shouldn’t change current prescribing practices. Semaglutide is already recommended for people with type 2 diabetes who meet certain criteria, and the drug has its own risks and side effects, including potential thyroid issues and stomach problems.

For now, the research offers compelling evidence that this already-popular medication might have benefits researchers are only beginning to understand. As clinical trials specifically designed to test semaglutide’s effects on cognitive decline move forward, we may soon have clearer answers about whether this diabetes drug could become a powerful weapon against dementia.